Redx Pharma Future Growth

Future criteria checks 0/6

Redx Pharma's revenue and earnings are forecast to decline at 37.6% and 22.3% per annum respectively while EPS is expected to decline by 14.2% per annum.

Key information

-22.3%

Earnings growth rate

-14.2%

EPS growth rate

Pharmaceuticals earnings growth	15.4%
Revenue growth rate	-37.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	02 Apr 2024

Recent future growth updates

Recent updates

Does Redx Pharma (LON:REDX) Have A Healthy Balance Sheet?

Aug 22

Is Redx Pharma (LON:REDX) Using Too Much Debt?

May 22

Bullish: Analysts Just Made A Significant Upgrade To Their Redx Pharma Plc (LON:REDX) Forecasts

Jul 09

Earnings and Revenue Growth Forecasts

AIM:REDX - Analysts future estimates and past financials data (GBP Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2025	N/A	-49	N/A	-48	1
9/30/2024	13	-26	N/A	-24	1
9/30/2023	4	-33	-35	-35	N/A
6/30/2023	8	-31	-32	-32	N/A
3/31/2023	13	-29	-30	-30	N/A
12/31/2022	16	-24	-19	-19	N/A
9/30/2022	19	-18	-9	-8	N/A
6/30/2022	17	-18	-8	-8	N/A
3/31/2022	16	-19	-8	-7	N/A
12/31/2021	13	-20	-15	-14	N/A
9/30/2021	10	-22	-22	-21	N/A
6/30/2021	8	-20	-15	-14	N/A
3/31/2021	7	-18	-7	-7	N/A
12/31/2020	6	-14	-4	-3	N/A
9/30/2020	6	-9	0	0	N/A
6/30/2020	5	-8	-2	-2	N/A
3/31/2020	4	-6	-5	-5	N/A
12/31/2019	4	-5	-5	-5	N/A
9/30/2019	3	-4	-5	-5	N/A
6/30/2019	2	-5	-6	-6	N/A
3/31/2019	N/A	-7	-8	-8	N/A
12/31/2018	0	-8	-13	-13	N/A
9/30/2018	0	-9	-17	-17	N/A
6/30/2018	15	-1	-4	-4	N/A
3/31/2018	31	8	9	9	N/A
12/31/2017	31	5	11	11	N/A
9/30/2017	30	2	14	14	N/A
6/30/2017	15	-9	N/A	-1	N/A
3/31/2017	N/A	-19	N/A	-16	N/A
12/31/2016	N/A	-17	N/A	-14	N/A
9/30/2016	N/A	-16	N/A	-13	N/A
6/30/2016	N/A	-14	N/A	-11	N/A
3/31/2016	N/A	-12	N/A	-9	N/A
12/31/2015	N/A	-10	N/A	-8	N/A
9/30/2015	N/A	-8	N/A	-7	N/A
6/30/2015	N/A	-7	N/A	-6	N/A
3/31/2015	N/A	-5	N/A	-5	N/A
12/31/2014	N/A	-4	N/A	-4	N/A
9/30/2014	N/A	-3	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: REDX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: REDX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: REDX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: REDX's revenue is expected to decline over the next 3 years (-37.6% per year).

High Growth Revenue: REDX's revenue is forecast to decline over the next 3 years (-37.6% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if REDX's Return on Equity is forecast to be high in 3 years time

Redx Pharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus EPS estimates upgraded to UK£0.062 loss

Price target decreased by 9.9% to UK£1.32

Consensus revenue estimates increase by 15%, EPS downgraded

Consensus revenue estimates increase by 24%

Consensus revenue estimates increase by 31%

Price target increased to UK£1.70

Recent updates

Redx Pharma Provides Update on AIM Delisting

New major risk - Share price stability

Consensus EPS estimates upgraded to UK£0.062 loss

Redx Announces That First Participant Dosed in Phase 1 Trial of RXC008

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Redx Pharma Plc, Annual General Meeting, Mar 14, 2024

New minor risk - Share price stability

New minor risk - Market cap size

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Redx Pharma Plc to Report Fiscal Year 2023 Results on Dec 15, 2023

New minor risk - Financial data availability

New minor risk - Shareholder dilution

Redx Pharma plc to Present Preclinical Data on RXC009, A Selective Discoidin Domain Receptor 1 Inhibitor

Redx Pharma Plc has completed a Follow-on Equity Offering in the amount of £14.059359 million.

Redx Pharma plc Appoints Joseph Anderson as Non-Executive Director

Redx Pharma Plc Announces Executive Changes

Does Redx Pharma (LON:REDX) Have A Healthy Balance Sheet?

Redx Pharma plc Zelasudil Receives FDA Orphan Drug Designation

New minor risk - Market cap size

Redx Pharma Plc Announces Directorate Changes

Is Redx Pharma (LON:REDX) Using Too Much Debt?

Price target decreased by 9.9% to UK£1.32

First half 2023 earnings released: UK£0.062 loss per share (vs UK£0.035 loss in 1H 2022)

Redx Pharma Plc's Discovery of Pirtobrutinib Recognised with Unveiling of Commemorative Plaque At Alderley Park

Redx Pharma Plc Presents Preclinical Efficacy Data for RXC007 Showing Significant Results in Cancer-Associated Fibrosis Models

Redx Pharma Plc to Report First Half, 2023 Results on May 17, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Redx Pharma Plc, Annual General Meeting, Mar 14, 2023

Redx Pharma Plc Provides Progress Updates on RXC007 Clinical Programme

Consensus revenue estimates increase by 15%, EPS downgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Redx Pharma Plc to Report Q4, 2022 Results on Dec 20, 2022

High number of new directors

Redx Pharma plc to Present on Potential of RXC007 in Fibrotic Diseases at Antifibrotic Drug Discovery Meeting

Redx Pharma plc Announces First Patient Dosed in Phase 2a Trial for RXC007

Bullish: Analysts Just Made A Significant Upgrade To Their Redx Pharma Plc (LON:REDX) Forecasts

Consensus revenue estimates increase by 24%

Consensus revenue estimates increase by 31%

Redx Pharma Announces Two Presentations Were Delivered at the Inaugural Extracellular Matrix Pharmacology Congress in Copenhagen, 23-25 June

First half 2022 earnings released

Redx Pharma Plc to Report Q2, 2022 Results on Jun 23, 2022

Redx Pharma Plc has completed a Follow-on Equity Offering in the amount of £34.261864 million.

Price target increased to UK£1.70

High number of new directors

Redx Pharma Plc Presents Encouraging RXC004 Preclinical Data

Redx Pharma plc Announces Nomination of Clinical Development Candidate

Redx Pharma Plc Announces Committee Changes

Redx Pharma Plc, Annual General Meeting, Mar 08, 2022

High number of new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

First half 2021 earnings released: UK£0.053 loss per share (vs UK£0.027 loss in 1H 2020)

Non-Executive Chairman Iain Ross has left the company

Redx Pharma Announces First Subject Dosed in Phase 1 Study with Lead Fibrosis Candidate RXC007, a ROCK2 Selective Inhibitor

Redx Pharma Announce Mead Will Step Down from the Board

Redx Pharma plc Announces Search for A US Based Chief Financial Officer Has Been Initiated

Chief Medical Officer has left the company

New 90-day high: UK£0.68

Redx Pharma Plc, Annual General Meeting, Mar 02, 2021

Earnings beat expectations, revenue disappoints

Redx Pharma Plc to Report Fiscal Year 2020 Results on Jan 27, 2021

New 90-day low: UK£0.54

Redx Pharma plc Announces the Appointment of Jane Robertson as Chief Medical Officer, Effective 1 March 2021

New 90-day high: UK£0.68

New 90-day high - UK£0.60

Redmile Group, LLC completed the acquisition of remaining 54.5% stake in Redx Pharma Plc (AIM:REDX).

Redx Pharma Plc announced that it expects to receive £23.63877 million in funding from Sofinnova Partners SAS, Redmile Group, LLC

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts